DF/HCC Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) Core Spotlight
Published 11/4/2025
The Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) is at the forefront of advancing cellular therapies, offering a suite of key services that are pivotal in the realm of medical oncology. CMCF specializes in the processing of hematopoietic stem cells for both autologous and allogeneic transplantation, genetic modification of these stem cells, generation of tumor vaccines, and the manufacture of genetically modified immune cells for adoptive cellular therapy. Additionally, the facility plays a crucial role in collecting and storing follow-up blood and bone marrow samples from subjects treated on cell therapy protocols, thereby supporting clinical investigators in achieving their research objectives.
At the helm of CMCF is Jose A. Cancelas, MD, PhD, the Executive Director, who brings a wealth of experience in transfusion medicine, cell therapies, hematology, and stem cell biology. Dr. Cancelas is responsible for overseeing cell manufacturing for stem cell transplantation and immune effector cell programs at Dana-Farber Cancer Institute. His role extends to supporting clinical research protocols across the consortium. With a distinguished career that includes leadership roles as Director and Chairman of the Hoxworth Blood Center and Director of the Translational Core Laboratories and Stem Cell Program of the Cancer & Blood Diseases Institute of Cincinnati Children's Hospital, Dr. Cancelas is a pivotal figure in the advancement of innovative cellular products, supported by the U.S. Government for over 20 years, and tested in various disease settings. Joining the leadership team is Carolyn Lutzko, PhD, the new Scientific Director. Dr. Lutzko brings over three decades of experience research in cell and gene therapy including a decade at Cincinnati Children’s Hospital Medical Center, where she directed the Cell Manipulation Laboratory and served as Interim Director of the Translational Core Laboratories. Her expertise in cell manipulation and translational research is a valuable addition to CMCF, promising to enhance the facility's capabilities in cutting-edge cellular therapies.
Under the guidance of these esteemed leaders, CMCF continues to push the boundaries of cellular therapy, ensuring that patients receive the most advanced and effective treatments available. With a focus on collaboration and innovation, the facility is poised to make significant strides in the fight against cancer and other diseases.